definiens: shall mean, collectively, patent n ts, ow- ow and 0er mte ec Q!opertyng ts own y, or lcen ( other than from CuraGenunder this Agreement ) to, ABX in ( a ) all antigens other than the Antigens ; ( b ) all GeneticMaterials that encode such antigens ; ( c ) all uses of such antigens ; ( d ) all antibodies ( whether ornot derived from the XenoMouse Animals ) or other compositions that bind to such antigens, Genetic Materials that encode such antibodies or compositions, Antibody Cells that contain, express or secrete such antibodies or Genetic Materials, and cells that contain, expressor secrete . such composition~ ( e)fill uses of such antibodies, Genetic Materials and compositio~ ; and ( f)all other materials, uses of materials, inventions, discoveries, data, information, methods, techniques, technology and other results related to or derived from the XenoMouse Animals ortheir use, whether or not patentable, other than ABX Technology and Information!1.32 shall mean, collectively, all patentn ts, ow- ow an 0er mte ec property rights owned by, or licensed ( other than fromABX under this Agreement ) to, CuraGen in ( a ) all data, information and materials related tohuman Genetic Materials and the expression products thereof which is not part of the CuraGenDatabases, is not related to Antigens or antibodies that bind thereto and is not Research ProgramTechnology and Information ; ( b)Lallmethods of using antig ~ ns other than for the research, development, and commercialization of antibodies ; and ( c ) ; ; IIother materials, uses of materials, inventions, discoveries, data, information, methods, techniques, technology and other results, whether or not patentable, other than CuraGen Technology and Information and ResearchPro Technolo and Information . '1.33 shall mean the United States Food and Drug Administration or itssuccessor agency